sirtex, resmed, csl and cochlear, page-3

re: sirtex I figure based on next years reveues of about 40 million and 10 million net or 19 cents a share in earnings this share at 10x P.E with over 100%+ growth is an undervaled bargain at this price of $2. Very rare example of co in Australia with an FDA approved product
in an expanding market. Managment has got its act together and looking for a double here short term. Dr Gray nearing 70 yrs probably itching to cash out too.